Dasatinib: A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

By McCormack Paul L.   Keam Susan J.  

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1771-1795

Adis International

Access to resources Recommend Favorite

Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia

By Fullmer Amber   Kantarjian Hagop   Cortes Jorge   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 3065-3072

Informa Healthcare

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

By  

Current Cancer Drug Targets, Vol. 12, Iss. 4, 2012-04 ,pp. : 391-401

Bentham Science Publishers

Access to resources Recommend Favorite

Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia

By Shimoni Avichai   Volchek Yulia   Koren-Michowitz Maya   Varda-Bloom Nira   Somech Raz   Shem-Tov Noga   Yerushalmi Ronit   Nagler Arnon  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 863-871

Blackwell Publishing

Access to resources Recommend Favorite

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure

By Hochhaus Andreas  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 18, 2007-12 ,pp. : 3257-3264

Informa Healthcare

Access to resources Recommend Favorite